Prabhakar NR. Reactive oxygen species-dependent endothelin signaling is required for augmented hypoxic sensory response of the neonatal carotid body by intermittent hypoxia. Am J Physiol Regul Integr Comp Physiol 296: R735-R742, 2009. First published December 24, 2008; doi:10.1152/ajpregu.90490.2008.-We previously reported that intermittent hypoxia (IH) augments hypoxic sensory response (HSR) and increases the number of glomus cells in neonatal carotid bodies. In the present study, we tested the hypothesis that recruitment of endothelin-1 (ET-1) signaling by reactive oxygen species (ROS) plays a critical role in IH-evoked changes in neonatal carotid bodies. Experiments were performed on neonatal rats exposed either to 10 days of IH (P0 -P10; 8 h/day) or to normoxia. IH augmented HSR of the carotid bodies ex vivo and resulted in hyperplasia of glomus cells. The effects of IH were associated with enhanced basal release of ET-1 under normoxia, sensitization of carotid body response to exogenous ET-1, and upregulation of ETA but not an ETB receptor mRNA without altering the ET-1 content. An ETA but not ETB receptor antagonist prevented augmented HSR by IH. ROS levels were elevated in carotid bodies from IH-treated rat pups as evidenced by increased levels of malondialdehyde. Systemic administration of manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride (MnTMPyP; 5 mg/kg ip), a scavenger of O2
recurrent apneas; premature infants; chemoreflex; arterial chemoreceptors; chronic intermittent hypoxia NEARLY 70% of prematurely born infants exhibit recurrent apneas (17) , which are characterized by repetitive cessations of breathing (ϳ2 breaths duration) leading to periodic decreases in arterial blood O 2 or intermittent hypoxia (IH). Infants having a larger number of apneas exhibit greater hypoxic ventilatory response (HVR) than those having a lesser number of apneas, and the enhanced HVR was attributed to augmented peripheral chemoreceptor reflexes from the carotid bodies, the principal sensory organs for detecting changes in arterial blood O 2 (12) . Studies on neonatal rat pups showed that IH augments the hypoxic sensory response (HSR) of the carotid body and HVR (13, 16) . The effects of IH on neonatal carotid bodies were associated with increased number of glomus cells (13) , the putative hypoxia sensing cells in the chemoreceptor tissue. However, the mechanisms associated with IH-evoked augmented HSR and hyperplasia of glomus cells in neonatal carotid bodies has not been examined.
In adult rats, IH increase reactive oxygen species (ROS) in the carotid body, and antioxidant treatment prevented IHevoked increases in HSR (14, 15) . Glomus cells of the carotid body express a variety of neurotransmitters/modulators that play important roles in hypoxic sensing/signaling (18) . In adult rat carotid bodies, endothelin-1 (ET-1) is expressed in few glomus cells, and IH upregulates ET-1 expression in glomus cells (20) . Bosentan, an ET-1 receptor antagonist, prevented IH-induced sensitization of the HSR (20) . In the present study, we tested the hypothesis that ROS-dependent upregulation of ET-1 signaling is important for IH-induced increase in HSR and hyperplasia of glomus cells in neonatal rat carotid bodies. Our results demonstrate that IH increases ROS in neonatal carotid bodies, and ROS-dependent upregulation of ET-1 release and ET A receptors contribute to the IH-induced increase in HSR but not to the hyperplasia of glomus cells.
MATERIALS AND METHODS
Experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Chicago. Experiments were performed on neonatal (P0 -P10) Sprague-Dawley rat pups.
Exposure to IH. Rat pups (ϳ2-6 h of age) along with their mothers were housed in feeding cages and exposed to IH as described previously (16) . Briefly, cages were placed in a specialized chamber that was flushed with alternating cycles of nitrogen gas and room air. During hypoxia, the inspired O 2 level reached a nadir of 5% O2 and was maintained at this level for 15 s. This was followed by room air (21% O 2), which was maintained for 5 min. The gas flows were regulated by timer-controlled solenoid valves. Animals were exposed to IH every day between 9:00 A.M. and 5:00 P.M. (9 episodes/h; 8 h/day). Ambient O 2 and CO2 levels in the chamber were monitored continuously. Ambient CO 2 levels in the chamber were maintained between 0.2 and 0.5%. Control experiments were performed on neonatal rats exposed to alternating cycles of room air instead of hypoxia in the same chamber. In experiments where the potential contribution of ROS was examined, rats were given manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride (MnTMPyP; 5 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ip; Alexis Biochemicals) every day before exposing them to IH or normoxia. Control experiments were performed on rats exposed to IH or normoxia treated with vehicle instead of MnTMPyP.
Acute experiments were performed after 6 -10 h following either IH or normoxia.
Measurement of malondialdehyde levels. Carotid bodies were homogenized in 10 vol of 20 mM phosphate buffer (pH 7.4) at 4°C. Malondialdehyde (MDA) levels were analyzed in supernatants as described previously (19) . Briefly, 12.5 l of sample or the calibration standard, MDA, were added to 6.25 l of 8.1% (wt/vol) SDS, 47 l of 20% (vol/vol) acetic acid, and 47 l of 0.8% (wt/vol) thiobarbituric acid. The samples were heated for 60 min followed by incubation for 10 min at room temperature and centrifuged at 3,000 g for 15 min. The supernatant was removed, and the absorbance of the solution was monitored at 532 nm. The results were expressed as nanomoles of MDA formed per milligram of protein.
Measurement of carotid body sensory activity. Sensory activity from ex vivo carotid bodies was recorded as described previously (13) . Briefly, carotid bodies along with the sinus nerves were harvested from anesthetized neonatal rats (urethane; 1.2 g/kg ip), placed in a recording chamber (250 l volume), and superfused with physiological saline (35°C) at a rate of 2 ml/min. The composition of the medium was (in mM) 125 NaCl, 5 KCl, 1.8 CaCl2, 2 MgSO4, 1.2 NaH 2PO4, 25 NaHCO3, 10 D-glucose, and 5 sucrose, and the solution was bubbled with 95% O 2-5% CO2. To facilitate recording of clearly identifiable action potentials, the sinus nerve was treated with 0.1% collagenase for 5 min. Action potentials (2-5 active units) were recorded from one of the nerve bundles with a suction electrode and stored in a computer via an A/D translation board (PowerLab/8P; AD Instruments). The criteria for chemoreceptor activity include increased sensory activity in response to hypoxia (ϳ30 Torr) and return to baseline after resuming the superfusion with O2 enriched medium. "Single" units were selected based on the height and duration of the individual action potentials using a spike discrimination program (Spike Histogram Program, Power Laboratory; AD Instruments). In each carotid body, at least two chemoreceptor units were analyzed. The PO 2 and PCO2 of the superfusion medium were determined by a blood gas analyzer (ABL 5; Radiometer, Copenhagen, Denmark).
Immunocytochemical and morphometric analysis of the carotid body. The protocols for fixation of carotid bodies were essentially the same as described previously (13) . Briefly, carotid bifurcations were harvested from anesthetized rat pups (1.2 g/kg ip urethane), placed in 4% paraformaldehyde for 4 h at room temperature, washed in PBS, and cryoprotected in 30% sucrose/PBS at 4°C for 24 h. Tissue specimens were frozen in optimum cutting temperature compound (Tissue Tek; VWR Scientific), serially sectioned at a thickness of 8 m, and stored at Ϫ80°C. For immunocytochemical analysis, carotid body sections were washed three times in PBS and exposed to 20% normal goat serum and 0.2% Triton X-100 in PBS for 30 min followed by incubation with the monoclonal mouse anti-tyrosine hydroxylase (TH; 1:2,000; Sigma) or polyclonal rabbit anti-bovine secretory protein-1/chromogranin A (CGA; 1:2,000; DiaSorin) or polyclonal rabbit anti-ET-1 (1:200; Peninsula Laboratories) in PBS with 1% normal goat serum and 0.2% Triton X-100. After being washed with PBS, sections were incubated for 1 h with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:250; Molecular Probes) or Texas red-conjugated goat anti-rabbit IgG (1:250; Molecular Probes) in PBS with 1% normal goat serum and 0.2% Triton X-100. After being washed with PBS, sections were mounted in 4,6Ј-diamidino-2-phenylindole (DAPI) containing media and visualized using a fluorescent microscope (Eclipse E600; Nikon). Specificity of the ET-1 staining was determined by incubations of sections with ET-1 antibody pretreated with an excess of ET-1 peptide. For morphometric analysis, carotid body morphology and glomic volume were analyzed in sections from age-matched control and IH pups using IMAGE software (Scion, Frederick, MD). For estimation of the number of glomus cells, cells stained positive for either TH or CGA and DAPI (nuclear staining) were counted using a mechanical cell counter in the NIH Image J software program.
Measurements of ET-1 content and release.
For measurements of ET-1 content, carotid bodies were harvested from anesthetized rat pups and homogenized in 10 vol of a mixture of 1 M acetic acid-20 mM HCl. The homogenate was boiled at 100°C and centrifuged at 13,000 g for 10 min at 4°C. The supernatant was removed and stored at Ϫ80°C until further analysis. The protocols for assessing the ET-1 release from the carotid bodies were essentially the same as described previously (7) . Briefly, carotid bodies harvested from anesthetized rat pups were incubated in 100 l of Ca 2ϩ -and/or Mg 2ϩ -free KrebsRinger-bicarbonate (KRB) medium preequilibrated with 95% O 2-5% CO 2 (hyperoxia) for 30 min at 4°C. Subsequently, tissues were transferred to a reaction vial and incubated at 37°C with 60 l of normal KRB medium equilibrated with appropriate gas mixtures (containing 5% CO 2) resulting in medium PO2 of either 150 Ϯ 3 mmHg (normoxia) or 35 Ϯ 2 mmHg (hypoxia) for 30 min. The medium and the carotid bodies were removed and stored at Ϫ80°C until further analysis. ET-1 levels were determined with a commercially available ET-1 enzyme immunoassay (EIA) kit (Assay Designs) following the manufacturer's instructions. All measurements were performed in duplicate. The detection limit of EIA was 0.41 pg/ml. ET-1 levels were expressed as picogram per milligram of protein in content experiments and as picogram per milligram per minute for release studies. Protein content was determined by Bio-Rad DC protein assay using bovine serum albumin as the standard.
Measurements of mRNA expression in the carotid body. Carotid bodies were harvested from anesthetized rat pups and homogenized, and RNA was extracted using TRIZOL (Invitrogen) according to the manufacture's instructions. For RT-PCR, 1 l of RNA was reverse transcribed using superscript III reverse transcriptase (Invitrogen). Primer sequences for RT-PCR amplification were as follows: ET-1 (377 bp), forward TCCAAGCGTTGCTCCTGCTC and reverse GT-TGCTGATGGCCTCCAACC; ET A receptor (570 bp), forward GAAGTCCTCGGTGGGGATCA and reverse CCGATGTAATC-CATGAGCAG; ETB (475 bp) receptor, forward TTCACCTCAG-CAGGATTCTG and reverse AGGTGTGGAAAGTTAGAACG; glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 452 bp), forward ACCACAGTCCATGCCATCAC and reverse TCCACCAC-CCTGTTGCTGTA. Initial denaturation was performed at 94°C for 2 min followed by an amplification phase of 35 cycles: 94°C for 90 s, 54°C for 60 s, and 72°C for 90 s. A final extension was carried out at 72°C for 7 min. PCR products were analyzed by gel electrophoresis on a 1% agarose gel stained with ethidium bromide. Band intensities were quantified using IMAGE software (Scion). Primer sequences for real-time RT-PCR amplification were as follows: ET-1 (133 bp), forward CCGAGCCCAAAGTACCATGC and reverse GCTGATG-GCCTCCAACCTTC; ETA receptor (119 bp), forward CTTCTG-CATGCCCTTGGTGT and reverse CTCGACGCTGCTTGAGG-TGT; ETB (117 bp) receptor, forward AAGTCGTGTTTGTGCT-GCTGGTG and reverse GCTGGAGCGGAAGTTGTCGT; and 18S rRNA (151 bp), forward GTAACCCGTTGAACCCCATT and reverse CCATCCAATCGGTAGTAGCG. Real-time PCR was carried out using a MiniOpticon system (Bio-Rad Laboratories, Hercules, CA) with SYBR green as a fluorogenic binding dye (Invitrogen). The reactions were incubated at 50°C for 2 min (action of uracil DNA glycosylase) then at 95°C for 8 min and 30 s (uracil DNA glycosylase inactivation and DNA polymerase activation), followed by 40 twostep cycles of 15 s at 95°C and 1 min at 60°C. The products were analyzed by Opticon Monitor software, using a standard curve. The values were normalized to its 18S rRNA. Purity and specificity of all products were confirmed by omitting the template and by appropriate size and single melting temperature.
Experimental protocols. In series 1, MDA levels (index of ROS) were determined in carotid bodies harvested from control (normoxia), IH, control ϩ MnTMPyP, and IH ϩ MnTMPyP treated pups (n ϭ 3 experiments in each group run in duplicate and 3 carotid bodies/ experiment). In series 2, the carotid body sensory response to graded hypoxia (medium PO2 ϭ 139 Ϯ 4, 70 Ϯ 5, and 34 Ϯ 4 mmHg and PCO2 ϭ 36 Ϯ 3 mmHg) was determined in control, IH, and IH ϩ MnTMPyP treated rat pups (n ϭ 7-8 carotid bodies from 4 pups from 3 different litters). Each level of hypoxia was maintained for 5 min followed by a recovery period of 5 min. In series 3, morphometric analysis of carotid bodies was performed on control, IH, and IH ϩ MnTMPyP treated rat pups (n ϭ 6 carotid bodies from 3 pups in each group) with two established markers of glomus cells: TH and CGA (9, 10) . In series 4, ET-1-like immunoreactivity in carotid body from control and IH-conditioned rat pups was determined (n ϭ 3 pups in each group). In series 5, ET-1 content of the carotid bodies was analyzed in control and IH-exposed rat pups by EIA (n ϭ 3 experiments run in duplicate; 10 carotid bodies/experiment). In series 6, basal and acute hypoxia evoked release of ET-1 from carotid bodies from control, IH, and IH ϩ MnTMPyP treated rat pups was determined by EIA (n ϭ 4 experiments each; 5 carotid bodies/experiment). In series 7, the effects of exogenous administration of ET-1 on HSR of the carotid body from control and IH-exposed rat pups were examined. HSR was recorded in the presence of vehicle or increasing concentrations of ET-1 (10 Ϫ15 to 10 Ϫ11 M). Carotid bodies were superfused for 5 min with each concentration of ET-1 before the hypoxic challenge (n ϭ 6 carotid bodies in each group). The concentrations of ET-1 were chosen from preliminary experiments. In series 8, mRNA levels of pre-pro-ET-1, ET A, ETB receptor, and GAPDH (housekeeping gene) were determined by RT-PCR and by real time RT-PCR in carotid bodies harvested from rat pups exposed to normoxia, IH, and IH ϩ MnTMPyP (3 individual experiments each; n ϭ 10 carotid bodies/experiment). In series 9, the effect of BQ-610 (an ETA antagonist) on carotid body response to graded hypoxia was determined. In the initial experiments (n ϭ 4), the effects of increasing concentrations of BQ-610 (30 nM, 100 nM, 300 nM, 1 M, and 3 M) on the sensory response to hypoxia (medium PO 2 ϭ 32 Ϯ 2 mmHg) were determined in IH-exposed neonatal carotid bodies. BQ-610 prevented IH-evoked augmentation of HSR in a dose-dependent manner, and maximal effect was seen with 1 M. Increasing the BQ-610 concentration to 3 M had no further attenuating effect on the HSR compared with 1 M. Based on these observations, 1 M of BQ-610 was chosen to examine the carotid body response to graded isocapnic hypoxia in IH and control rat pups (n ϭ 7 carotid bodies from 7 pups). The results were compared with the effects of equimolar concentrations of BQ-788 (1 M), an ET B antagonist on the HSR of the IH-exposed carotid body (n ϭ 7 carotid bodies).
Data analysis. Carotid body sensory activity (discharge from single units) was analyzed every 10 s for 5 min at baseline and during the entire period of hypoxia, and the data were averaged and expressed as impulses per second. The data were analyzed as absolute values or delta impulse per second (i.e., hypoxia Ϫ baseline activity). All data are presented as means Ϯ SE. Statistical significance was assessed by two-way ANOVA with repeated measures followed by Tukey's test. P Ͻ 0.05 were considered significant.
RESULTS

ROS mediates IH-induced augmented HSR but not the morphological changes in the carotid body.
MDA levels were monitored in carotid bodies from IH and normoxia-treated rat pups as an index of ROS (19) . MDA levels were approximately sixfold higher in IH-exposed carotid bodies compared with controls (P Ͻ 0.005), and MnTMPyP, a potent scavenger of O 2
•Ϫ , abolished this response (Fig. 1) . To determine the involvement of ROS, we examined the effects of MnTMPyP on the IH-evoked increase in HSR. To this end, the effects of graded hypoxia on the sensory response of the ex vivo carotid body were determined in IH-exposed rat pups with and without treatment with MnTMPyP. Control experiments were performed on carotid bodies isolated from IH pups treated with vehicle (saline). As shown in Fig. 2 HSR was augmented in IH-treated carotid bodies compared with controls (i.e., carotid bodies from normoxia-exposed pups), and MnTMPyP treat- and IH-exposed P10 rat pups treated with MnTMPyP (5 mg/kg ip every day from P0 -P10). Horizontal black bar represents the duration of the hypoxic challenge (Hx; medium PO2 ϭ 30 -32 mmHg). Insets represent superimposed action potentials from a single unit from which the data were derived. B: average data of the carotid body responses to graded isocapnic hypoxia (medium PCO2 ϳ35-36 mmHg) in control (ᮀ), IH (■), and IH exposure combined with MnTMPyP treatment (OE). Data presented are means Ϯ SE from 7 carotid bodies from 7 rat pups in each group. **P Ͻ 0.005 (control vs. IH). ment abolished this response. The magnitude of the remaining HSR in IH rats treated with MnTMPyP was nearly the same as in the control carotid bodies harvested from rat pups reared under normoxia (Fig. 2B) .
To test whether ROS contributes to IH-induced changes in the morphology of the carotid bodies, morphometric analysis was performed on carotid bodies from control and IH-exposed rat pups with and without MnTMPyP treatment. Carotid bodies were stained for TH or CGA, established markers of glomus cells (9, 10) . Both TH and CGA yielded qualitatively similar results. Therefore, results obtained with TH are summarized in Table 1 . Glomic cell volume and the ratio of glomic volume to total cell volume, as well as the number of glomus cells (analyzed with DAPI ϩ TH-stained cells) were significantly increased in IH-treated carotid bodies, and MnTMPyP treatment had no significant effect on these variables (P Ͼ 0.05; Table 1 ).
Effect of IH on ET-1 expression in neonatal carotid bodies.
To begin to assess the role of ET-1 in IH-induced upregulation of HSR, we first monitored ET-1-like expression in carotid bodies from rat pups exposed to IH or normoxia. ET-1-like immunoreactivity was expressed in many glomus cells in the control carotid bodies as evidenced by colocalization with TH, a marker of glomus cells (Fig. 3A) . The specificity of ET-1 staining was confirmed by the absence of ET-1 staining following incubation of carotid body sections with ET-1 antibody treated with excess of ET-1 peptide before immunostaining (Fig. 3A, right) . In IH-treated carotid bodies, ET-1 expression was comparable with control carotid bodies from rat pups reared under normoxia. Because immunocytochemistry provides only qualitative information, ET-1 peptide levels were quantified in IH and control carotid bodies by EIA. Control carotid bodies expressed substantial ET-1-like peptide (23 Ϯ 2 pg/mg of protein), and IH had no significant effect on carotid body ET-1 levels (25.7 Ϯ 2.8 pg/mg of protein; control vs. IH, P Ͼ 0.05; Fig. 3B ). Analysis of pre-pro-ET-1 mRNA expression in the carotid bodies by conventional RT-PCR revealed no significant differences between control and IH-exposed tissues (Fig. 3C) , which was further confirmed by real time RT-PCR.
IH augments ET-1 release from the carotid bodies. We examined whether IH affects ET-1 release from the carotid body. Basal release of ET-1 under normoxia (medium PO 2 ϭ 150 Ϯ 3 mmHg) was 33% higher in IH compared with control carotid bodies (P Ͻ 0.005), which was absent in carotid bodies from IH-exposed rat pups treated with MnTMPyP (Fig. 4A) . On the other hand, ET-1 release by acute hypoxia (medium PO 2 ϭ 35 Ϯ 2 mmHg) was comparable in control, IH, and IH-exposed rat pups treated with MnTMPyP ( Fig. 4B ; P Ͼ 0.05).
IH sensitizes carotid body response to exogenous ET-1. A previous study reported that exogenous ET-1 potentiates HSR without altering the baseline activity in adult rabbit carotid body (2) . The following experiments were performed to assess whether IH affects the potentiating effects of ET-1 on HSR. In these experiments, the effects of increasing concentrations of ET-1 were examined on the carotid body sensory response to moderate hypoxia (medium PO 2 ϭ ϳ60 mmHg) because severe hypoxia might saturate the sensory response confounding interpretation of results. In control carotid bodies, hypoxia augmented the sensory activity by ϩ2.2 Ϯ 0.6 ⌬impulses/s. ET-1 had no effect on HSR at 10 Ϫ15 M, whereas at 10 Ϫ12 M, it significantly augmented HSR without altering the baseline activity (Fig. 5A, left) . Increasing ET-1 concentration to 10 Ϫ11 M, however, attenuated HSR. In contrast, in IH-exposed carotid bodies, comparable levels of hypoxia evoked a greater HSR compared with controls, and 10 Ϫ15 M ET-1 evoked small but significant potentiation of HSR (Fig. 5, right) . Increasing ET-1 concentrations to either 10 Ϫ12 or 10 Ϫ11 M attenuated HSR in IH-treated carotid bodies (Fig. 5B) .
IH upregulates ET A but not ET B receptor mRNA in neonatal carotid bodies. Biological actions of ET-1 are mediated by ET A and ET B receptors (21) . To determine whether IH influences ET-1 receptors, ET A and ET B receptor mRNA expression was analyzed in control and IH carotid bodies by RT-PCR. ET A receptor mRNA expression was ϳ3.5-fold higher in IH compared with controls (Fig. 6 ). This increase in ET A mRNA was not seen in IH carotid bodies treated with MnTMPyP. On the other hand, ET B receptor mRNA expression levels were comparable in control, IH, and IH ϩ MnTMPyP treated carotid bodies (Fig. 6) . Quantitative real-time RT-PCR approach was employed to further validate the results obtained with RT-PCR. Real-time RT-PCR analysis revealed that IH treatment increased ET A mRNA expression by 548% relative to controls. MnTMPyP treatment prevented IH-induced upregulation of ET A mRNA expression (41% increase). Similar to the data with the RT-PCR approach, IH had no significant effect on ET B mRNA expression.
ET A but not ET B receptor antagonist prevents IH-induced upregulation of HSR. The effects of BQ-610, an ET A receptor antagonist, on the carotid body response to graded hypoxia were examined in carotid bodies from IH and control rat pups. Based on preliminary studies (see MATERIALS AND METHODS), we chose 1 M of BQ-610 for these studies. As shown in Fig. 7 , BQ-610 prevented IH-induced augmentation of HSR, whereas it had no significant effect on the HSR in control carotid bodies. The effects of BQ-610 completely reversed within 20 min after removing the antagonist from the superfusate ( Fig.  7A; far right) . On the other hand, 1 M of BQ-610 had no effect on carotid body sensory response to depolarizing stimulus (40 mM KCl). More importantly, BQ-788, an ET B receptor antagonist at equimolar concentrations (1 M), tended to potentiate the HSR in IH-exposed carotid bodies, but this effect was not significant (IH ϭ ϩ20 Ϯ 1 ⌬impulses/s vs. BQ-788 ϭ ϩ26 Ϯ 3 ⌬impulses/s; P Ͼ 0.05). Fig. 4 . Effect of IH on ET-1 release from neonatal carotid bodies. A: average data of basal ET-1 release during normoxia (medium PO2 ϭ 145 Ϯ 2 mmHg) from carotid bodies harvested from control, IH-exposed rat pups treated without (IH) and with MnTMPyP. B: average data of hypoxia-evoked ET-1 release from the same preparations. Data presented are means Ϯ SE from n ϭ 16 carotid bodies in each group. **P Ͻ 0.005 (control vs. IH). NS, not significant (P Ͼ 0.05; control vs. IH). Consistent with earlier reports (13, 16) , we found that IH augments HSR in neonatal rat carotid bodies. A previous study reported that IH upregulates ET-1, and ET-1 receptors mediate the IH-evoked increase in the HSR of the adult cat carotid body (20) . Based on this study, we examined whether IH also upregulates ET-1 in neonatal carotid bodies. To this end, we employed three approaches, including immunocytochemistry, EIA, and real-time RT-PCR. Neonatal rat carotid bodies expressed substantial ET-1, and much of the peptide was localized to glomus cells. However, unlike the adult cats, IH had no significant effect either on ET-1 expression or pre-pro-ET-1 mRNA levels in neonatal carotid bodies. It is likely that the inability of IH to alter ET-1 expression is due to high levels of basal ET-1 expression in neonatal carotid bodies.
Although ET-1 expression was unaffected, IH significantly enhanced the basal ET-1 release from neonatal carotid bodies. Studies on the effects of exogenous ET-1 showed that as little as femtomolar concentration augmented HSR in IH-treated neonatal carotid bodies, whereas picomolar concentration, which is 1,000 times higher, was needed to augment HSR in control carotid bodies. These observations taken together suggest that IH-evoked enhanced basal ET-1 release leads to greater sensitization of HSR in IH compared with control carotid bodies. How might ET-1 lead to greater sensitization of HSR in neonatal carotid bodies? Biological actions of ET-1 are mediated via ET A and ET B receptors (21) . IH led to an ϳ3.5-fold increase in ET A mRNA in neonatal carotid bodies, whereas it had no effect on ET B receptor mRNA. More importantly, ET A but not ET B receptor antagonist prevented IH-evoked sensitization of the HSR. The effects of ET A blocker were selective to hypoxia because carotid body re- sponse to depolarizing stimulus (40 mM KCl) was unaffected by ET A antagonist. These observations suggest that upregulation of ET A receptors contributes to IH-evoked upregulation of HSR and sensitization of ET-1 response in neonatal carotid bodies. Further studies, however, are required to examine the localization of ET A receptors in the carotid body and the effects of IH on ET A receptor protein and affinity to ET-1. It is interesting to note that higher concentrations of ET-1 lead to marked attenuation of HSR in IH-treated carotid bodies. This attenuated HSR might conceivably be because of ET B receptor-dependent activation of nitric oxide synthesis (6), which is known to inhibit the carotid body sensory activity (23) .
What signaling mechanism(s) contributes to IH-evoked enhanced ET-1 release and upregulation of ET A receptor mRNA? The following observations demonstrate a role for ROS as an upstream signaling molecules(s) mediating the effects of IH. First, IH increased ROS levels in neonatal carotid bodies as evidenced by elevated MDA levels. Second, and perhaps more important evidence was that antioxidant treatment prevented IH-evoked increases in ROS, blocked the sensitization of the HSR, and enhanced ET-1 release and the upregulation of the ET A receptor mRNA by IH.
How might ROS mediate enhanced ET-1 release and increases in ET A receptor mRNA? Recent studies have shown that ROS generated by IH activates intracellular Ca 2ϩ -mobilizing pathways, which in turn contribute to IH-evoked transcriptional activation (24, 11) . It is likely that ROS-mediated Ca 2ϩ signaling contributes to the upregulation of ET A receptor mRNA in IH-treated neonatal carotid bodies. Future studies are needed to confirm this possibility. Weak stimulation of neuronal cells tends to promote partial release of the vesicular transmitter content via a kiss-and-run mechanism, which accounts for the release of low molecular weight transmitters such as biogenic amines. On the other hand, stronger stimuli elicit either a more complete emptying of the vesicle content or alternatively cause vesicles to undergo full fusion, resulting in enhanced secretion, including neuropeptides of high molecular weight (4, 5) . Our recent study on the effect of IH on hypoxic response of the rat neonatal chromaffin cells showed that IH recruits additional Ca 2ϩ -signaling pathways via ROS-dependent mechanisms, leading to stronger intracellular Ca 2ϩ concentration responses and enhanced quantal transmitter release (D. Souwannakitti, G. K. Kumar, A. P. Fox, and N. R. Prabhakar, unpublished observations). We believe that similar ROS-dependent Ca 2ϩ signaling may contribute to the augmented ET-1 release from the carotid body by IH (D. Souwannakitti, G. K. Kumar, A. P. Fox, and N. R. Prabhakar, unpublished observations). Although our data indicate that ROS is the upstream signal for ET-1, there are reports suggesting that ET-1 generates ROS by activating NADPH oxidase (3). Further studies are needed to examine whether ET-1 generates ROS and contributes to ROS-induced ROS in IH-treated neonatal carotid body.
Consistent with our earlier study (13) , IH significantly increased the number of glomus cells in neonatal carotid body. However, unlike its effects on HSR, antioxidant treatment was ineffective in preventing IH-elicited hyperplasia of glomus cells. These observations suggest that the heightened HSR by IH was not secondary to an increased number of glomus cells. Although these results suggest ROS signaling may not be contributing to IH-evoked morphological changes, ET-1 could still be driving the hyperplasia via non-ROS mechanism(s), a possibility that remains to be further investigated.
Perspective and Significance
In summary, the results of the present study demonstrate that ROS-dependent recruitment of ET-1 signaling contributes to IH-induced heightened hypoxic sensitivity but not to the hyperplasia of glomus cells. What might be the significance of altered carotid body sensitivity to hypoxia by IH in neonatal life? It has been suggested that the enhanced hypoxic sensitivity of the carotid bodies leads to destabilization of breathing, making the system prone to apneas (1) . Consequently, we proposed that IH-induced heightened HSR of neonatal carotid bodes might perpetuate apneas (13) . Indeed, a recent study showed that IH leads to a larger number of apneas in neonatal rat pups, and this effect was associated with augmented HVR (8), indicating augmented carotid body reflexes. In future studies, it would be interesting to examine whether ET-1 receptor antagonist prevents worsening of apneas in IH-treated neonatal rat pups. Such studies might be of considerable significance in providing novel therapeutic strategies for alleviating the physiological consequences of breathing disorders in premature infants.
